Difference between revisions of "Samarium-153 (Quadramet)"
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.<ref name="insert">[http:// | + | Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.<ref name="insert">[http://www.lantheus.com/assets/quadramet-us-outsert-513145-0114-format-2-3-4-2014.pdf Samarium-153 (Quadramet) package insert]</ref><ref>[[Media:Samarium153a.pdf|Samarium-153 (Quadramet) package insert (locally hosted backup)]]</ref><ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000150/WC500041751.pdf Samarium-153 (Quadramet) alternative package insert]</ref><ref>[[Media:Samarium153b.pdf|Samarium-153 (Quadramet) alternative package insert (locally hosted backup)]]</ref><ref>[http://www.lantheus.com/products/overview/quadramet/ Quadramet manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Bone cancer ]] | + | *[[Bone cancer]] |
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 3/28/1997: Initial FDA approval | + | *3/28/1997: Initial FDA approval "for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan." |
==Also known as== | ==Also known as== | ||
| Line 25: | Line 25: | ||
[[Category:Radioactive agents]] | [[Category:Radioactive agents]] | ||
| − | [[Category:Bone cancer medications]] [[Category:Prostate cancer medications]] | + | [[Category:Bone cancer medications]] |
| + | [[Category:Prostate cancer medications]] | ||
[[Category:Drugs FDA approved in 1997]] | [[Category:Drugs FDA approved in 1997]] | ||
Revision as of 04:42, 17 March 2017
General information
Class/mechanism: Radioactive pharmaceutical agent (Samarium-153) that concentrates in areas of bone turnover associated with hydroxyapatite and releases beta and gamma radiation. Samarium-153 accumulates in osteoblastic lesions about 5 times as much as normal bone. Samarium-153's half-life is 46.3 hours.[1][2][3][4][5]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 3/28/1997: Initial FDA approval "for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan."
Also known as
153-Sm-EDTMP, 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP), Lexidronam Pentasodium, Quadramet, Samarium [153 SM], Samarium Sm 153 Lexidronam Injection, samarium Sm 152 oxide, 152Sm2O3.
References
- ↑ 1.0 1.1 Samarium-153 (Quadramet) package insert
- ↑ Samarium-153 (Quadramet) package insert (locally hosted backup)
- ↑ Samarium-153 (Quadramet) alternative package insert
- ↑ Samarium-153 (Quadramet) alternative package insert (locally hosted backup)
- ↑ Quadramet manufacturer's website
- ↑ Samarium-153 (Quadramet) patient drug information (UpToDate)